Melanoma Dispatch
2.6K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

What Cancer Costs You Later: $4,000 a Year

What Cancer Costs You Later: $4,000 a Year | Melanoma Dispatch | Scoop.it

"Having cancer is bad enough. And the lifetime consequences have been well-documented — a higher risk of other cancers, heart disease and general weakness from the treatment.


"Now a new federal study shows there’s a financial burden too — on average, $4,000 a year for men and $3,000 for women over and above what people who haven’t had cancer spend.


"And that’s just direct medical costs. Cancer survivors also have thousands in lost productivity, from having to cut work hours or even quit their jobs, the report finds."

Cancer Commons's insight:

NBC News  |  Jun 12, 2014

more...
Cancer Commons's curator insight, June 16, 2014 2:20 PM

NBC News  |  Jun 12, 2014

Cancer Commons's curator insight, June 16, 2014 2:20 PM

NBC News  |  Jun 12, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Living With Cancer: The Cost of Trials

Living With Cancer: The Cost of Trials | Melanoma Dispatch | Scoop.it

"A recent CT scan made me realize that the clinical trial extending my life effectively excludes all but the most privileged cancer patients.

"I used to weasel out of scans. Chalk it up to trepidation about radiation and possible kidney damage, along with paranoid suspicions that such scans don’t yield definitive pictures. My oncologist and I had agreed to fudge on frequent testing. But the clinical trial did not."


Editor's Note: Learn more about clinical trials here.

Cancer Commons's insight:

The New York Times  |  Mar 20, 2014

more...
Cancer Commons's curator insight, March 21, 2014 2:45 PM

The New York Times  |  Mar 20, 2014

Cancer Commons's curator insight, March 21, 2014 3:51 PM

The New York Times  |  Mar 20, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Realizing the Full Benefits of Palliative Care

Realizing the Full Benefits of Palliative Care | Melanoma Dispatch | Scoop.it

Evidence is mounting for the manifold benefits of palliative care–which is focused on alleviating symptoms–for cancer patients. Studies have shown that cancer patients who receive palliative care experience higher quality of life, less depression, and are better functioning. They also live longer, even though fewer of them undergo aggressive end-of-life care. Thanks to fewer hospitalizations, greater use of palliative care also actually decreases health care costs. Nonetheless, both physicians and patients often shy away from palliative care, as it is frequently–though falsely–associated with death and dying. Unlike hospice care, however, palliative care is intended and appropriate for all patients, regardless of stage or prognosis. Advocates recommend that palliative care should be offered widely and early on in cancer treatment.

Cancer Commons's insight:

Healio  |  Nov 10, 2013

more...
Cancer Commons's curator insight, December 3, 2013 6:30 AM

Healio  |  Nov 10, 2013

Cancer Commons's curator insight, December 3, 2013 6:22 PM

Healio  |  Nov 10, 2013

Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

IMS Study Shows Cancer Treatment Costs Driven Up by 340B Drug Pricing Program

IMS Study Shows Cancer Treatment Costs Driven Up by 340B Drug Pricing Program | Melanoma Dispatch | Scoop.it

"The IMS Institute for Healthcare Informatics issued a detailed report titled, 'Innovations in Cancer Care and Implications for Health Systems,' and the Alliance for Integrity and Reform of 340B said the report shows that the drug discount program is a driver in the rise in treatment costs for patients with cancer."

Cancer Commons's insight:

Healio  |  May 13, 2014

more...
Cancer Commons's curator insight, May 13, 2014 3:13 PM

Healio  |  May 13, 2014

Cancer Commons's curator insight, May 13, 2014 3:13 PM

Healio  |  May 13, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Cancer Doctors Have Opportunities to Cut Costs Without Risk to Patients, Experts Say

Cancer Doctors Have Opportunities to Cut Costs Without Risk to Patients, Experts Say | Melanoma Dispatch | Scoop.it

"In a review article published Feb. 14 in The Lancet Oncology, Johns Hopkins experts identify three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging and drug pricing.


" 'We need to find the best ways to manage costs effectively while maintaining the same, if not better, quality of life among our patients,' says Thomas Smith, M.D., The Harry J. Duffey Family Professor of Palliative Medicine and professor of oncology at Johns Hopkins."

Cancer Commons's insight:

Medical Xpress  |  Feb 14, 2014

more...
Cancer Commons's curator insight, February 14, 2014 1:29 PM

Medical Xpress  |  Feb 14, 2014

Cancer Commons's curator insight, February 14, 2014 1:29 PM

Medical Xpress  |  Feb 14, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

U.S. Doctors Begin to Question High Cost of Cancer Medicines

U.S. Doctors Begin to Question High Cost of Cancer Medicines | Melanoma Dispatch | Scoop.it

Cancer drug prices have risen dramatically since the early 2000s, especially in the U.S. Some doctors are beginning to balk at medications that, in some cases, can cost over $10,000 a month and often offer only marginal improvements in survival. Other drugs do produce dramatic increases in life expectancy, but accumulating expenses force patients to stop treatment. Several aspects of the U.S. drug market contribute to high prices, including long patent durations that shield drug makers from competition, and Medicare’s inability to negotiate better prices with drug makers. Health authorities in several other countries have started to refuse coverage for drugs that, in their estimation, do not offer enough benefit to warrant their high cost. Notably, cancer drug prices in those countries are significantly lower than in the U.S. In 2012, Memorial Sloan-Kettering Cancer Center became the first major U.S. hospital to refuse offering a cancer drug–zif-aflibercept (Zaltrap)–due to price concerns.

Cancer Commons's insight:

New York Magazine | Oct 20, 2013

more...
Cancer Commons's curator insight, October 23, 2013 10:36 AM

New York Magazine | Oct 20, 2013

Cancer Commons's curator insight, October 23, 2013 2:03 PM

New York Magazine | Oct 20, 2013